CLDX
Celldex Therapeutics·NASDAQ
--
--(--)
--
--(--)
4.40 / 10
Netural
Analyst coverage is minimal, with one Sell rating and no Buy/Hold votes, reflecting pessimism. However, fund flows are robust (7.88/10), showing net inflows across block and extra-large transactions despite small-medium outflows. This divergence hints at institutional accumulation that could counteract negative analyst sentiment.
Fund Flow Rating
Analyst RatingSell
Wall Street Opinions
Sell
Strong Buy
0%
Buy
0%
Hold
0%
Sell
100%
Strong Sell
0%
Date2025-12-17
InstitutionBarclays
Times predicted3
Historical Win Rate33.3%
Is money flowing into or out of CLDX?
- CLDX holds a Bearish analyst rating, with 100% of experts assigning a Sell grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 4.40/10 (Netural).
